comprehensive -WSS

comprehensive

author：leisure time 2025-08-28 13:07:39 - browse：4317

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Ozempic has benefits for kidney disease as well as diabetes

WSS

Ozempic has benefits for kidney disease as well as diabetes

After John Oliver segment, STAT readers share their opioid

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Lack of health data on LGBTQ+ people has serious consequences

Why Talkspace is targeting Medicare, a tricky market

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

How one medical school became remarkably diverse

An innovative path out of biotech’s “valley of death”

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biden's 'march

The cancer drug shortage isn’t new — and neither are the solutions

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Fetal cell organoids grown from amniotic fluid, study finds

How one medical school became remarkably diverse

$1 billion proposal to grow Boston, Massachusetts biotech

hotspot

CDC overhauls leadership of center that led response to Covid

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

Change Healthcare: What is it, why does its cyberattack matter?

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

CDC overhauls leadership of center that led response to Covid

An innovative path out of biotech’s “valley of death”

leisure time

hotspot

Wikipedia

explore